Endo International (NASDAQ:ENDP) (TSE:ENL) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday, September 8th.

Other equities analysts have also issued reports about the company. Deutsche Bank set a $11.00 target price on Endo International and gave the stock a “buy” rating in a research report on Wednesday, July 18th. ValuEngine raised Endo International from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. B. Riley increased their price target on Endo International from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, August 7th. Citigroup reissued a “buy” rating on shares of Endo International in a research report on Wednesday, July 11th. Finally, TheStreet raised Endo International from a “d” rating to a “c-” rating in a research report on Monday, August 20th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $14.07.

Shares of NASDAQ:ENDP traded down $0.16 during trading on Friday, reaching $15.89. 2,860,746 shares of the stock were exchanged, compared to its average volume of 3,913,977. The company has a quick ratio of 0.91, a current ratio of 1.07 and a debt-to-equity ratio of -132.64. Endo International has a 1-year low of $5.27 and a 1-year high of $17.46. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of 4.14, a PEG ratio of 3.12 and a beta of 0.74.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.22. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The company had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. During the same period in the prior year, the firm earned $0.93 earnings per share. Endo International’s revenue for the quarter was down 18.4% on a year-over-year basis. equities research analysts anticipate that Endo International will post 2.6 earnings per share for the current fiscal year.

In other news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total transaction of $414,576.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.80% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Xact Kapitalforvaltning AB increased its position in shares of Endo International by 44.5% during the 1st quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock valued at $174,000 after purchasing an additional 9,000 shares during the last quarter. Neuburgh Advisers LLC increased its position in shares of Endo International by 84.2% during the 1st quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock valued at $215,000 after purchasing an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC increased its position in shares of Endo International by 83.9% during the 1st quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock valued at $245,000 after purchasing an additional 18,800 shares during the last quarter. Tyers Asset Management LLC increased its position in shares of Endo International by 84.2% during the 1st quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock valued at $274,000 after purchasing an additional 21,084 shares during the last quarter. Finally, Flinton Capital Management LLC increased its position in shares of Endo International by 84.2% during the 1st quarter. Flinton Capital Management LLC now owns 55,998 shares of the company’s stock valued at $333,000 after purchasing an additional 25,602 shares during the last quarter. 98.43% of the stock is owned by hedge funds and other institutional investors.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Leveraged Buyout (LBO) Explained

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.